Takeda jumps into Humira space

Share this article:
Takeda jumps into Humira space
Takeda jumps into Humira space

The FDA announced a new contender in the ulcerative colitis and Crohn's disease treatment space: Takeda, which scored approval of its infusion drug Entyvio for adults with moderate-to-severe forms of both diseases. The drug is indicated for patients who have not had an adequate response to previous treatments.

The OK puts the drugmaker in the mix with injectable peers including AbbVie's blockbuster Humira, which accounted for 57% of the Illinois drugmaker's 2013 sales, and has already provided nearly $3 billion to its sales so far this year. Part of Humira's power is its ability to attract new indications, which include Tuesday's news that the FDA granted orphan drug status for the established medication in the context of non-infectious anterior uveitis, a rare inflammatory eye disease.

The space has also been an asset for Johnson & Johnson, whose Remicade—also a drug with multiple indications—garnered almost $7 billion in 2013 sales, and has brought in $1.6 billion as of this year's first quarter.

Although Takeda is stepping into a competitive space, the category still has room. As noted on medical websites such as Mayo Health, patients may need to not just try multiple medications to alleviate their conditions, but may find that they no longer respond to a once-reliable medication.

Takeda's entrant has the added appeal of a different mechanism of action: unlike Humira and Remicade, which are anti tumor necrosis factors, or anti-TNFs, Entyvio is an integrin receptor antagonist.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.